The investigational MRI contrast agent, gadoquatrane, is designed to deliver effective imaging at a significantly reduced ...

Bayer BAYRY announced that it has submitted a new drug application (“NDA”) to the FDA seeking approval for its ...

Berlin: Bayer has announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for ...

The company's application included a submitted dose of 0.04 millimole gadolinium per kilogram of body weight. If approved, gadoquatrane would become the lowest dose macrocyclic gadolinium-based ...

The DEA Museum explores Bayer's early 20th-century marketing of heroin, originally promoted as a "less addictive" morphine alternative and cough suppressant. Initially hailed as a medical ...

Bayer seeks US FDA approval for contrast agent, gadoquatrane for contrast-enhanced MRI of the CNS and other body regions: Berlin Wednesday, June 18, 2025, 09:00 Hrs [IST] Bayer an ...